Is there a "Trial Effect" on Outcome of Patients with Metastatic Renal Cell Carcinoma Treated with Sunitinib?

PURPOSE: Studies suggested the existence of a ‘trial effect', in which for a given treatment, participation in a clinical trial is associated with a better outcome. Sunitinib is a standard treatment for metastatic renal cell carcinoma (mRCC). We aimed to study the effect of clinical trial parti...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Cancer Res Treat
Main Authors: Keizman, Daniel, Rouvinov, Keren, Sella, Avishay, Gottfried, Maya, Maimon, Natalie, Kim, Jenny J., Eisenberger, Mario A., Sinibaldi, Victoria, Peer, Avivit, Carducci, Michael A., Mermershtain, Wilmosh, Leibowitz-amit, Raya, Weitzen, Rony, Berger, Raanan
Format: Artigo
Jezik:Inglês
Izdano: Korean Cancer Association 2016
Teme:
Original Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC4720089/
https://ncbi.nlm.nih.gov/pubmed/25761478
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4143/crt.2014.289
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki